Gossamer Bio, Inc.
GOSS
NASDAQ·Healthcare·Biotechnology·Mkt cap $85.7M
$0.18
▼ -0.17%
P/E
—
Mkt Cap
$85.7M
52-Wk Range
$0.11–$3.87
52-Week Range
$0.11 - $3.87
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 93.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Targeted delivery mechanisms (inhaled and gut-targeted formulations) for improved efficacy and reduced systemic toxicity
- Strategic partnerships with specialized biotech companies (Pulmokine, Aerpio Pharmaceuticals) providing development expertise and resources
- Diversified pipeline across multiple therapeutic areas reducing single-program dependency risk
- Focus on validated biological targets (PDGFR, CSF1R, BTK) with established clinical relevance
Bear Case
1 risk
- High volatility (beta 2.0). Larger-than-normal price swings expected.
Growth
Revenue decline expected
Clinical trial progression and potential FDA approvals for GB002, GB004, GB5121, and GB7208
Value
Valuation data unavailable
Momentum
Strong
+5.9% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying GOSS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 13, 2026
Reported EPS of -$0.08 vs -$0.12 consensus (+35.2% surprise). Revenue of $9.2M vs $3.6M expected (+154.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+35.2%
Revenue trend · last 8Q
—
—
—
-88%
+40%
+47%
+71%
-20%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$9.5M
$9.4M
$9.9M
$11.5M
$13.3M
$13.8M
$17.0M
$9.2M
Margins · last 8Q
Gross
0.0%
Profit
182.9%
Wall Street consensus
4 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
25%
Sell
25%
Median Price Target
—
Latest: HC Wainwright · Aug 27, 2026
vs Industry
How GOSS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related